Primary imatinib, 2002-2008 (CML IV) 5-year survival 93% n = 2830 Survival probability IFN or SCT, 1997-2008 (CML IIIA) 5-year survival 71% IFN or SCT, 1995-2008 (CML III) 5-year survival 63% IFN, 1986-2003 5-year survival 53% Hydroxyurea, 1983-1994 Busulfan, 1983-1994 5-year survival 38% Year after diagnosis German CML Study Group, 2008
Wikipedia, 2007 http://www.glivec.jp/video/index.html
Isotani M, JVIM, 2008 Druker BJ, J Clin Invest, 2000 Cohen MH, Clin Cancer Res, 2002
London CA, Clin Cancer Res, 2003 London CA, Vet Compar Oncol, 2011 McQuown B, VCS Proc, 2014 Berger EP, ACVIM Proc, 2017 London CA, Clin Cancer Res, 2003 London CA, Clin Cancer Res, 2009 London CA, Clin Cancer Res, 2003 Bernabe LF, BMC Vet Res, 2013
Bernabe LF, BMC Vet Res, 2013 London CA, Clin Cancer Res, 2003
London CA, Clin Cancer Res, 2009 ALT London CA, Clin Cancer Res, 2009 p=0.003 10
1042 10 66 10 100 13GIST 34
p= Tjostheim SS, JVIM, 2016; Azizi M, N Engl J Med, 2008; Demetri GD, Lancet, 2006; Chu TF, KLancet, 2007; Maki RG, J Clin Oncol, 2005; Kane RC, Clin Cancer Res, 2006 Rassnick KM, JVIM, 1999 Rassnick KM, JVIM, 2008 Henry CJ, JAVMA, 2007 Rassnick KM, JVIM, 2008 Weishaar KM, JVIM, 2017 Rassnick KM, Vet Comp Oncol, 2010 McCaw DL, JVIM, 1997 Grant IA, JVIM, 2008 McCaw DL, JVIM, 1994 Stanclift RM, JAVMA, 2008,, 2009 * Rassnick Henary Rassnick ** SD 1
n Thamm DH, JVIM, 1999 Camps-Palau MA, Vet Comp Oncology, 2007 Taylor F, JSAP, 2009 Cooper M, Vet Comp Oncol, 2009 Rassnick KM, Vet Comp Oncol, 2010 1. Rassnick KM, JVIM, 1999, 2. Rassnick KM, JVIM, 2008, 3. Henry CJ, JAVMA, 2007, 4. Rassnick KM, JVIM, 2008, 5. Rassnick KM, Vet Comp Oncol, 2010, 6. Thamm DH, JVIM, 1999, 7. Camps-Palau MA, Vet Comp Oncol, 2007, 8. Taylor F, JSAP, 2009, 9. Cooper M, Vet Comp Oncol, 2009, 10. Rassnick KM, Vet Comp Oncol, 2010, 11. Weishaar KM, JVIM, 2017 VBL: CPM: PRD n Thamm DH, JVIM, 1999 Davies DR, JAAHA, 2004 Hayes A, Vet Comp Oncol, 2007 Camps-Palau MA, Vet Comp Oncol, 2007 Cooper M, Vet Comp Oncol, 2009 Rassnick KM, Vet Comp Oncol, 2010 * c-kit Downing S, Am J Vet Res, 2002 Zemke D, Vet Pathol, 2002
n KIT KIT - - 1. Hahn KA, JVIM, 2008, 2. Smrkovski OA, Vet Comp Oncol, 2013, 3. London CA, Clin Cancer Res, 2009 4. Weishaar KM, JVIM, 2017 Hahn KA, JVIM, 2008 London CA, Clin Cancer Res, 2009 London CA, Clin Cancer Res, 2009
n KIT % KIT KIT 1. Isotani M, JVIM, 2008, 2:,, 2010, 3. Robat C, Vet Comp Oncol, 2012, 4. Burton JH, JVIM, 2015 5. Grant J, JSAM, 2016 110 9 33 224
p=0.002 Burton JH, JVIM, 2015 p=0.07 Smrkovski OA, Vet Comp Oncol, 2013 c-kit p=0.009 p=0.008 p=0.274 p=0.411 Hahn, KA, JVIM, 2008 c-kit c-kit
PDGFR= VEGFR= London CA, Vet Compar Oncol, 2011 % n=32 n=23 n=15 n=8 n=7 London CA, Vet Compar Oncol, 2011
London CA, Vet Compar Oncol, 2011 London CA, Vet Compar Oncol, 2011 p= Kim C, Can Vet J, 2017 Laver T, Vet Compar Oncol, 2017
More? McQuown B, VCS Proc, 2014
21 21
2cm Berger EP, ACVIM Proc, 2017 13 MGIST c-kit 28 246 13 MGIST c-kit 28 246
n= 126) Piro CPM: London C, PLos One, 2015 n= 81) p=0.274 p=0.08 Piro CPM: London C, PLos One, 2015 Gardner HL, BMC Vet Res, 2015
Robat C, Vet Comp Oncol, 2012 Rippy SB, BMC Vet Res, 2016 Pan X, Vet Comp Oncol, 2014 Burton JH, JVIM, 2015
Bavcar S, Vet J, 2017 Pellin MA, Vet Comp Oncol, 2016 Wounda RM, Vet Comp Oncol, 2017
Lachowicz JL, JVIM, 2005 c-kit Isotani M, Br J Haematol, 2010 Isotani M, Vet Immunol Immunopathol, 2006 p= Olmsted GA, J Feline Med Surg, 2016
Merrick CH, Vet Comp Oncol. 2016 Harper A, J Feline Med Surg, 2016
Berger EP, J Feline Med Surg, 2017 p p Wiles V, J Feline Medicine and Surgery, 2016
OS PFS p=0.0042 p=0.0038 Wiles V, J Feline Medicine and Surgery, 2016 13 2.8mg/kg EOD N. Holtermann, Vet Comp Oncol. 2017
c-kit